Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN ... wrote as he projected further upside for the stock given a mid-stage readout expected for CYBN’s anxiety ...

On Wednesday, Canaccord Genuity revised its price target for Cybin Inc. (NYSE:CYBN) shares, reducing it to $73.00 from the previous $86.00, while continuing to endorse the stock with a Buy rating.

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Several other research analysts also recently commented on the stock. Canaccord Genuity Group cut their price objective on shares of Cybin from $86.00 to $73.00 and set a “buy” rating for the ...

Cybin Inc. (CYBN) has been beaten down lately with too much selling pressure. While the stock has lost 25.8% over the past four weeks, there is light at the end of the tunnel as it is now in ...